The 510(k) decision clears the device for use with ultra-rapid-acting insulins from Eli Lilly and Novo Nordisk.
The US FDA has approved Medtronic’s 780G for use with rapid-acting insulin and with Abbott’s type 2 diabetes-specific sensor.
GlobalData on MSN
Medtronic achieves three milestones for MiniMed 780G system in US
Beneficiaries of Medicare and Medicare Advantage can now obtain the MiniMed 780G system combined with the Instinct sensor.
Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced three significant U.S. milestones that ...
Medtronic has collected a European approval that allows it to combine its latest automated insulin pump with its newest glucose sensor for the first time. The CE mark covers the MiniMed 780G pump and ...
DUBLIN, Jan. 8, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced CE (Conformité Européenne) Mark approval for the MiniMed™ 780G system with ...
Medtronic (NYSE:MDT) announced an agreement to acquire CathWorks, aiming to add AI-powered coronary artery disease tools to ...
TOLOCHENAZ, SWITZERLAND - Medtronic, Inc. today announced the European launch of MiniMed® Duo(TM), the world's first two-in-one breakthrough that combines a glucose sensor and insulin infusion set ...
With CE Mark approval, the benefits of the MiniMed™ 780G system are now available with a new sensor that takes less than 10 seconds to insert1 DUBLIN, Jan. 8, 2024 /PRNewswire/ -- Medtronic plc ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results